Literature DB >> 23581279

SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol.

Magdalena Sedek1, Ger J Strous.   

Abstract

Jak2 (Janus kinase 2) initiates the signal transduction of many cytokine receptors. We discovered that Jak2 is SUMOylated on multiple lysine residues by SUMO2/3 (small ubiquitin-related modifier 2/3) chains. Analysis of Jak2 mutants revealed that Jak2 SUMOylation depends on the presence of an active catalytic site. We used the GH (growth hormone) receptor to study the physiological relevance of Jak2 SUMOylation. Both GH stimulation and several other environmental stressors increased Jak2 SUMOylation. Cell fractionation showed that SUMOylated Jak2 is mainly present in the nucleus. The constitutively active V617F Jak2 mutant, implicated in myeloproliferative diseases, was highly SUMOylated in the absence of stimuli. These data provide evidence that Jak2 SUMOylation controls Jak2 shuttling between cytoplasm and nucleus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581279     DOI: 10.1042/BJ20121375

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

1.  Posttranslational modifications in proteins: resources, tools and prediction methods.

Authors:  Shahin Ramazi; Javad Zahiri
Journal:  Database (Oxford)       Date:  2021-04-07       Impact factor: 3.451

2.  Multimeric growth hormone receptor complexes serve as signaling platforms.

Authors:  Magdalena Sedek; Lieke M van der Velden; Ger J Strous
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

Review 3.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

4.  C-terminal Src kinase (Csk)-mediated phosphorylation of eukaryotic elongation factor 2 (eEF2) promotes proteolytic cleavage and nuclear translocation of eEF2.

Authors:  Qi Yao; Bing-Qian Liu; Hui Li; Deirdre McGarrigle; Bo-Wen Xing; Mao-Tian Zhou; Zhe Wang; J Jillian Zhang; Xin-Yun Huang; Lin Guo
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

5.  JAK2 inhibitor CEP-33779 prevents mouse oocyte maturation in vitro.

Authors:  Changli Wu; Rong Li; Haibing Luo; Mingfeng Xu; Xiujuan Zhang
Journal:  Biosci Rep       Date:  2017-07-12       Impact factor: 3.840

6.  SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.

Authors:  Jing Li; Ruiqin Wu; Mingo M H Yung; Jing Sun; Zhuqing Li; Hai Yang; Yi Zhang; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan; John C Braisted; Wei Zheng; Huiqiang Wei; Yingtang Gao; Peter Nemes; Huadong Pei; David W Chan; Yiliang Li; Wenge Zhu
Journal:  Cell Death Dis       Date:  2021-04-01       Impact factor: 8.469

7.  Inhibition of SENP6 restrains cerebral ischemia-reperfusion injury by regulating Annexin-A1 nuclear translocation-associated neuronal apoptosis.

Authors:  Qian Xia; Meng Mao; Zhen Zeng; Zhenzhao Luo; Yin Zhao; Jing Shi; Xing Li
Journal:  Theranostics       Date:  2021-06-01       Impact factor: 11.556

8.  SUMO1 modification of KHSRP regulates tumorigenesis by preventing the TL-G-Rich miRNA biogenesis.

Authors:  Haihua Yuan; Rong Deng; Xian Zhao; Ran Chen; Guofang Hou; Hailong Zhang; Yanli Wang; Ming Xu; Bin Jiang; Jianxiu Yu
Journal:  Mol Cancer       Date:  2017-10-11       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.